🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Efficacy and Safety Study of Ultra-early Mobile Stroke Unit Neuroprotection Combined With Revascularization for Acute Ischemic Stroke (EXCELLENT)

RecruitingPhase 4Ages 18 Years - 80 YearsAllRuijun Ji
NCT07119021 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

EXCELLENT was a prospective, multicenter, randomized, double-blind, placebo-controlled clinical study in which participants were randomized participants were randomized (1:1) to receive either IV thrombolysis + edaravone or IV thrombolysis + matched placebo (same volume of tablets without drug components), and the primary outcome was the proportion of patients with transformed bleeding on MRI at 72 hours following revascularization therapy.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Age 18-80 years; * Acute ischemic stroke as defined by the International Health Organization (WHO) and confirmed by cranial CT; * Onset within a 4.5-hour time window; * NIHSS score of 6-24; * Meet the criteria for intravenous thrombolysis in acute ischemic stroke recommended by international guidelines; * Patient or family consent. Exclusion Criteria: * Pregnant women, women in labor, and patients in the puerperium; * Comorbidity with other serious diseases that affect outcome determination; * Comorbidity with other serious diseases that affect prognostic regression; * Comorbidity with other serious diseases with a life expectancy of less than 1 year;
💊

What it tests

  • Intravenous thrombolysis + edaravone
  • IV thrombolysis + placebo (control group)
📍

Where

1 site
Beijing Tiantan Hospital of Capital Medical University
Beijing, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy